Last reviewed 2026-06-10 · How we verify

Pseudomonas gastrointestinal tract infection — Treatment Landscape & Competitive Intelligence

Pseudomonas gastrointestinal tract infection (disease) competitive landscape: 1 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

Marketed treatment landscape

Approved drugs treating Pseudomonas gastrointestinal tract infection, deduplicated by molecule. See the full disease page for line-of-therapy detail.

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

1. Merck & Co. · 1 drug in Pseudomonas gastrointestinal tract infection

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Pseudomonas gastrointestinal tract infection:

• Pseudomonas gastrointestinal tract infection treatment updates — RSS
• Pseudomonas gastrointestinal tract infection treatment updates — Atom
• Pseudomonas gastrointestinal tract infection treatment updates — JSON

Cite this brief

Drug Landscape (2026). Pseudomonas gastrointestinal tract infection — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/pseudomonas-gastrointestinal-tract-infection. Accessed 2026-06-10.

Related

• Pseudomonas gastrointestinal tract infection full disease profile — treatment pathway, diagnostics, guidelines
• Browse all CI briefs
• Build a custom feed

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing